SPECIAL REPORT
MOST SHARED
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Dipping Into Green Investing
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- For Investors, The New Green Looks To Be White
- Analysis: APEC Nations Back Face-Saving Climate Plan
- U.S. May Wind Up Green With Envy
- The Cost of Thanksgiving Dinner 2009
- Finding Value and Growth In The Green Sector
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Shift Into High-Quality Stocks Could Move Market Higher
- China: Low US Interest Rates Threaten Recovery
- Drug Study Questions Effectiveness of Merck's Drugs
- Military Arms Race Dominates Dubai Air Show
- Disaster Film '2012' Drowns Rivals at Box Office
- Cramer: 5 Earnings Reports to Watch Next Week
- Cities With the Most Home Price Reductions
- This Year's Biggest Thanksgiving Leftover: Cash
RSS FEED
Pharma's Market
I thought I was going to be able to skip town for the Rose Bowl without needing to bang out another blog before my plane takes off. I was wrong.
This morning Eli Lilly announced what many analysts had been speculating for months was probably going to happen. The company's all-important bloodthinner Effient will be reviewed by an FDA Advisory Committee in early February.
These outside panels of experts are called on to examine drugs — especially if there are questions about safety — and are asked to make recommendations to the FDA about what to do. The agency usually, but not always, takes the advice.
In this case, there are concerns that Effient may do such a good job thinning the blood of certain patients that they bleed too much.
In the press release, J. Anthony Ware, M.D., Lilly vice president and cardiovascular/acute care platform leader for Effient, is quoted as saying, "We have full confidence in the data submitted to the FDA and the overall benefit-risk profile of prasugrel, and we look forward to this next step in potentially bringing an important new alternative to the oral antiplatelet market."
(Prasugrel is the generic, scientific name for Effient. )
The FDA has already twice delayed making a decision on whether to approve Effient, which it had put on a fast track for action. Lilly has repeatedly said the filing was ginormous -- that if you printed it out, the paper would stack nearly as high as the Empire State building.
Nevertheless, for months now Lilly [LLY
Loading...
()
] has been promoting Effient at scientific conferences and in medical publications, saying, "Coming Soon."
Bristol-Myers Squibb [BMY
Loading...
()
] and Sanofi-Aventis [SNY
Loading...
()
] are having the last laugh. They own the bloodthinner Plavix, which will get to continue to be the unchallenged 800-pound gorilla in that space for at least a little while longer.
Questions? Comments?









